Research Looks at Reducing Antipsychotics for Learning Disabilities

Kermit Cole
2
51

Research at the University of Cardiff  School of Medicine is exploring whether and how people with learning disabilities, only one in six of whom have ever displayed symptoms of psychosis, can be safely withdrawn from antipsychotics. “The study is investigating an approach to reduce one of the greatest concerns in the healthcare of people with learning disabilities: Sedating medication is prescribed when it isn’t effective, significantly reducing people’s quality of life and their ability to integrate into society.”

Article →

Previous articleNIH Awards $1.2M to Study Side Effects of Antipsychotics
Next articleReduction/Discontinuation of Antipsychotics Produces Higher Long-Term Recovery
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected]

2 COMMENTS

  1. Why are people with learning disabilities being given the so-called “antipsychotics” in the first place? People who have challenges with learning certainly don’t need to be given something that screws up your thinking and keeps you from being able to connect with your emotions! These so-called “treatments” are nothing more than tranquilizers, period. How are they going to help people with learning disabilities?

LEAVE A REPLY